Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROZAC vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder with or without agoraphobia,Premenstrual dysphoric disorder,Bipolar depression (in combination with olanzapine)
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Fluoxetine: 4-6 days; norfluoxetine: 4-16 days; extensive accumulation with chronic dosing, steady-state in 4-5 weeks
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Hepatic via CYP2D6, CYP2C9, CYP2C19, and CYP3A4; active metabolite norfluoxetine.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Renal: ~80% (primarily as metabolites, <10% unchanged); fecal: ~15%
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
~94.5% bound to albumin and alpha-1-acid glycoprotein
94% bound to albumin and alpha-1-acid glycoprotein
12-42 L/kg; extensive tissue binding, particularly in lungs and brain
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral: 60-80% due to first-pass metabolism; not administered parenterally
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
GFR 10-50 m L/min: administer 50% of usual dose; GFR <10 m L/min: administer 50% of usual dose or use alternative; not removed by hemodialysis.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh Class A: no dose adjustment needed; Child-Pugh Class B: reduce dose by 50% or use alternative; Child-Pugh Class C: contraindicated or use alternative with caution.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Children 7-17 years: 10-20 mg orally once daily, initially; may increase to 20-40 mg once daily after ≥1 week; maximum 40 mg once daily.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Consider starting dose of 10 mg orally once daily; may increase slowly to 20 mg once daily; maximum 40 mg once daily; monitor for hyponatremia and QT prolongation.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in pediatric patients,Activation of mania/hypomania,QT interval prolongation,Serotonin syndrome,Discontinuation syndrome,Bleeding risk (with NSAIDs/aspirin)
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Hypersensitivity to fluoxetine,Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide or thioridazine
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
Avoid grapefruit juice as it inhibits CYP3A4 and may increase fluoxetine levels. Alcohol may potentiate CNS depression; advise minimal or no alcohol use. No other significant food interactions.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third trimester: Exposure is associated with risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (including irritability, respiratory distress, feeding difficulty). Second trimester: No specific major risks identified beyond general population baseline.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk. Milk-to-plasma ratio for fluoxetine is approximately 0.29. Infant serum levels can reach up to 10% of maternal therapeutic levels, with norfluoxetine accumulating. Adverse effects reported include irritability, poor feeding, and colic. American Academy of Pediatrics considers fluoxetine as a drug with 'potentially significant' effects; caution is advised, and breastfeeding should be weighed against maternal need.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
Pregnancy can decrease fluoxetine levels due to increased volume of distribution and hepatic metabolism; dose may need to be increased (20-40% on average) in third trimester, with tapering postpartum to pre-pregnancy dose to avoid toxicity. Therapeutic drug monitoring is recommended to maintain efficacy. No specific dose adjustment is standardized; individualization based on clinical response and serum levels is required.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Commonly used in bulimia nervosa (60 mg/day) and premenstrual dysphoric disorder (20 mg/day continuously or 20 mg/day only during luteal phase). Requires 4-6 weeks for full therapeutic effect. Abrupt discontinuation may cause withdrawal symptoms; taper over 2-4 weeks. Risk of serotonin syndrome when combined with MAOIs, other serotonergic drugs, or linezolid. Lower starting dose (10 mg) in hepatic impairment or elderly. Suicidality warning especially in children, adolescents, and young adults.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take exactly as prescribed, usually once daily in the morning to minimize insomnia.,It may take 4-6 weeks to feel full benefit; do not stop abruptly.,Do not take with MAOIs or within 14 days of stopping MAOIs.,Report any suicidal thoughts, especially during the first few weeks.,Avoid alcohol and grapefruit juice as they may increase side effects.,If you miss a dose, skip it; do not double the next dose.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROZAC vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
PROZAC is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROZAC and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROZAC is: 20 mg orally once daily, initially; may increase to 40 mg once daily after several weeks; maximum 80 mg once daily.. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROZAC and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROZAC is classified as Category C. First trimester: Studies suggest a small increased risk of cardiovascular malformations, particularly ventricular septal defects, with relative risk approximately 1.5-1.7. Third tr. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.